Meet the New Frontrunners in the Race for a COVID-19 Vaccine
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
All Work
Chris Lange
T2 Biosystems Solidifies Its Position as a COVID-19 Stock With New Test
T2 Biosystems solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.
FedEx Delivers in Q4, And Then Some
FedEx reported fiscal fourth-quarter financial results after markets closed Tuesday. The firm reported $2.53 in earnings per share (EPS) and $17.4 billion in revenue, compared with consensus estimates that called for $1.52 in EPS…
Zynerba Cannabinoid Investors Must Now Refocus on Treating Autism
Zynerba Pharmaceuticals shares were practically halved on Tuesday on news that its cannabis-based gel did not see statistically significant results from its most recent study.
Is OptiNose the Next Big Coronavirus Stock?
OptiNose shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.
Why This Parkinson’s Study Could Be Huge
Alterity Therapeutics says it has received an update from the FDA regarding its Parkinson’s treatment. That made shareholders happy.
How Speculative Biotech 9 Meters Biopharma Could Rise Tenfold
9 Meters Biopharma may not be a household name right now, but one brokerage firm sees huge potential upside.
Are Analysts Too Optimistic on Micron After Earnings?
Investors appear to be happy with the Micron Technology quarterly report, and analysts agreed, hiking their price targets in response.
Conagra Brands Lifted as Americans Stock Up on Snacks, Frozen Food
Conagra Brands reported better than expected fiscal fourth-quarter financial results before the markets opened on Tuesday.
Why Micron Earnings Were a Smash
DRAM maker Micron reported fiscal third-quarter earnings per share of $0.82and $5.44 billion in revenue. The consensus estimates called for $0.77 in per-share profit and $5.31 billion in revenue.
What This Capital Injection Means for Altimmune
Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.
Lancadia Goes All In on Online Gambling
News that Landcadia Holdings II aims to acquire Golden Nugget Online Gaming had its shares jumping to start out the week.
Meet the Newest Company to Make the Coronavirus Stock List
More investors now consider waste removal and cleaning company BioHiTech Global to be among those on the growing list of COVID-19 stocks. Thus, its shares more than doubled to start out the week.
Gilead Moves Forward With Pricing Its COVID-19 Treatment
Gilead has priced its COVID-19 drug candidate at $2,340 for a five-day treatment in the United States and some other developed countries. The company set the price for a single vial of remdesivir at…
What This FDA Update Means for Intercept Pharma
Intercept Pharmaceuticals stock was crushed early on Monday after the firm received an update from the FDA in regards to its treatment of fibrosis due to nonalcoholoic steatohepatitis.
Personal Income Pulls Back as Government Benefits Weaken
Despite a massive recovery in the stock market and trillions of dollars of stimulus, the U.S. economy is firmly in a recession. Friday’s round of economic numbers seemed to reflect this.
What Merger Hopes Mean for MDC Partners Stock
MDC Partners shares more than doubled on Friday after the company announced that it may be looking intently at a merger with Stagwell Media.
Albertsons Finally Gets Around to Coming Public
Albertsons has priced its initial public offering below the expected price range. Look for the food and drug retailer to come public later on Friday.
Nike’s Incredible Digital Sales Fail to Offset Store Closures
Nike released disappointing fiscal fourth-quarter financial results after the markets closed on Thursday, and shares slipped early Friday.
6 Stocks to Buy With Major Upside in Rising Secular E-Commerce Shifts
E-commerce has been perhaps the biggest winner from the coronavirus pandemic. These stocks are expected to benefit greatly from this accelerating trend.